Fate Therapeutics has treated the first patient with systemic lupus erythematosus using FT819, an off-the-shelf CD19-targeted CAR-T cell therapy derived from induced pluripotent stem cells.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.